Up-regulated DDX39 in Adrenocortical Carcinoma Is Associated With Patient Survival.

IF 1.7 4区医学 Q4 ONCOLOGY Anticancer research Pub Date : 2025-02-01 DOI:10.21873/anticanres.17469

Yoshiatsu Tanaka, Shin-Nosuke Yamashita, Shajedul Islam, Takao Kitagawa, Kazuhiro Tokuda, Durga Paudel, Sarita Giri, Tohru Ohta, Fumiya Harada, Hiroki Nagayasu, Yasuhiro Kuramitsu

{"title":"Up-regulated DDX39 in Adrenocortical Carcinoma Is Associated With Patient Survival.","authors":"Yoshiatsu Tanaka, Shin-Nosuke Yamashita, Shajedul Islam, Takao Kitagawa, Kazuhiro Tokuda, Durga Paudel, Sarita Giri, Tohru Ohta, Fumiya Harada, Hiroki Nagayasu, Yasuhiro Kuramitsu","doi":"10.21873/anticanres.17469","DOIUrl":null,"url":null,"abstract":"Background/aim: Adrenocortical carcinoma is a very rare tumor characterized by poor prognosis and high mortality. The origin of this tumor is primarily the adrenal cortex. The 5-year overall survival rate of patients with adrenocortical carcinoma has not improved despite therapeutic advances. Early detection of this malignancy remains difficult, and no standard curative therapy currently exists. Therefore, it is important to understand the biology of adrenocortical carcinoma, and to identify prognostic biomarkers and molecular targets for its therapy. DDX39 is an Asp-Glu-Ala-Asp (DEAD)-box RNA helicase, which is required for transcription, splicing and transport of mRNA. There are some reports about overexpression of DDX39 in tumor tissues and cells (lung squamous cell cancer, gastrointestinal stromal tumor, urinary bladder cancer, malignant pleural mesothelioma). However, the clinicopathological involvement of DDX39 in adrenocortical carcinoma has not yet been documented.Materials and methods: The GEPIA, GEPIA2, and UALCAN platforms were used to analyze DDX39 mRNA expression and survival in patients with adrenocortical carcinoma.Results: DDX39 was found to be significantly up-regulated in adrenocortical carcinoma tissues, and this up-regulation inversely correlated with prolonged patient survival.Conclusion: DDX39 may be a potential prognostic biomarker in patients with adrenocortical carcinoma.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 2","pages":"811-815"},"PeriodicalIF":1.7000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17469","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Adrenocortical carcinoma is a very rare tumor characterized by poor prognosis and high mortality. The origin of this tumor is primarily the adrenal cortex. The 5-year overall survival rate of patients with adrenocortical carcinoma has not improved despite therapeutic advances. Early detection of this malignancy remains difficult, and no standard curative therapy currently exists. Therefore, it is important to understand the biology of adrenocortical carcinoma, and to identify prognostic biomarkers and molecular targets for its therapy. DDX39 is an Asp-Glu-Ala-Asp (DEAD)-box RNA helicase, which is required for transcription, splicing and transport of mRNA. There are some reports about overexpression of DDX39 in tumor tissues and cells (lung squamous cell cancer, gastrointestinal stromal tumor, urinary bladder cancer, malignant pleural mesothelioma). However, the clinicopathological involvement of DDX39 in adrenocortical carcinoma has not yet been documented.

Materials and methods: The GEPIA, GEPIA2, and UALCAN platforms were used to analyze DDX39 mRNA expression and survival in patients with adrenocortical carcinoma.

Results: DDX39 was found to be significantly up-regulated in adrenocortical carcinoma tissues, and this up-regulation inversely correlated with prolonged patient survival.

Conclusion: DDX39 may be a potential prognostic biomarker in patients with adrenocortical carcinoma.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肾上腺皮质癌中DDX39表达上调与患者生存相关

背景/目的：肾上腺皮质癌是一种非常罕见的肿瘤，预后差，死亡率高。这种肿瘤的起源主要是肾上腺皮质。尽管治疗进步，肾上腺皮质癌患者的5年总生存率并没有提高。早期发现这种恶性肿瘤仍然很困难，目前没有标准的治疗方法。因此，了解肾上腺皮质癌的生物学，确定预后的生物标志物和治疗的分子靶点是很重要的。DDX39是一种Asp-Glu-Ala-Asp (DEAD)-box RNA解旋酶，是mRNA转录、剪接和转运所必需的。DDX39在肿瘤组织细胞（肺鳞状细胞癌、胃肠道间质瘤、膀胱癌、恶性胸膜间皮瘤）中有过表达的报道。然而，DDX39在肾上腺皮质癌中的临床病理参与尚未有文献记载。材料与方法：采用GEPIA、GEPIA2、UALCAN平台分析肾上腺皮质癌患者DDX39 mRNA表达及生存情况。结果：DDX39在肾上腺皮质癌组织中显著上调，且上调与患者生存期延长呈负相关。结论：DDX39可能是肾上腺皮质癌患者潜在的预后生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.